Article thumbnail

From antiangiogenesis to hypoxia: current research and future directions

By Christopher Rice and L Eric Huang


Angiogenesis has long been recognized as an essential element in tumor growth. Since the conception of antiangiogenesis for cancer therapeutics, great strides have been made in understanding the molecular biology underlying angiogenesis, both in cancer and in physiology. By capitalizing on these advancements through bench-to-bedside research, potent antiangiogenic agents have been developed and tested. To date, the clinical results of most of these antiangiogenic agents have not met expectations. Even with the most successful agents, such as bevacizumab, used either as single agents or in combination with chemotherapy, gains in overall survival of cancer patients have been modest in most cases. In this article, the authors present the evolving views of antiangiogenic therapy, review recent experimental and clinical studies on antiangiogenesis, and address the fundamental role of hypoxia in tumor progression, which may be key to improving the efficacy of antiangiogenic therapy

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. A corneal factor that induces neovascularization.
  2. Angiogenic factors.
  3. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.
  4. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor.
  5. Heterologous transplantation of mammalian tumors: I. The transfer of rabbit tumors to alien species.
  6. Interleukin-8 as a macrophage-derived mediator of angiogenesis.
  7. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning.
  8. (1991). Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell.
  9. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.
  10. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck.
  11. Preservation of vascular integrity in organs perfused in vitro with a platelet-rich medium.
  12. (1995). Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis.
  13. Thalidomide is an inhibitor of angiogenesis.
  14. (1997). The biology of vascular endothelial growth factor. Endocr Rev.
  15. Tumor angiogenesis: therapeutic implications.
  16. (1966). Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Ann Surg.
  17. (1995). Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med.
  18. Vascular endothelial growth factor is a secreted angiogenic mitogen.
  19. Vascular permeability factor, an endothelial cell mitogen related to PDGF.
  20. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants.
  21. Vascularization of the Brown–Pearce rabbit epithelioma transplant as seen in the transparent ear chamber.
  22. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.